WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 8, 2006--Charles River Laboratories International, Inc. (NYSE: CRL - News) Charles River Laboratories International, Inc. (NYSE: CRL - News) today reported second-quarter and year-to-date 2006 financial results. Beginning this period, the Company is reporting results from continuing operations, reflecting its strategic portfolio realignment to focus on its core competencies in research models and preclinical services. As a result of the of the intended sale of the Clinical Phase II - IV business and closure of the Interventional and Surgical Services (ISS) business (announced on May 9, 2006), these businesses are now reported as discontinued operations, and the Company has reclassified historical comparisons accordingly.
